10th IAS Conference on HIV Science (IAS 2019): final reports
30 September 2019. Related: Conference reports.
IAS 10 Mexico City 2019
Low rates of pregnancy with three methods of contraception in the ECHO trial
30 September 2019. Related: Conference reports, Pregnancy.
Other pregnancy studies IAS 2019
17 September 2019. Related: Conference reports, Pregnancy.
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
23 August 2019. Related: Conference reports.
Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
23 August 2019. Related: Conference reports, Treatment strategies.
Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
23 August 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
23 August 2019. Related: Conference reports, Antiretrovirals, Treatment strategies, Side effects.
Dolutegravir for younger children: results from the ODYSSEY trial
23 August 2019. Related: Conference reports, Paediatric care.
PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study
23 August 2019. Related: Conference reports, HIV prevention and transmission.
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
24 July 2019. Related: Conference reports.
Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals
24 July 2019. Related: Conference reports, Pregnancy.
WHO recommends dolutegravir-based ART regimens for all
24 July 2019. Related: Conference reports, Guidelines.
First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10
24 July 2019. Related: Conference reports, Antiretrovirals.
Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results
24 July 2019. Related: Conference reports, Antiretrovirals.
Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy
24 July 2019. Related: Conference reports, Antiretrovirals.
Fostemsavir: 96-week follow-up in people with multi-drug resistance
24 July 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96
24 July 2019. Related: Conference reports, Antiretrovirals.